Unichem Labs inches up after USFDA approval

Unichem Laboratories rose 1.07% to Rs 194.15 at 14:55 IST on BSE after the company got ANDA approval from USFDA for Pramipexole Dihydrochloride Tablets.

The announcement was made after market hours on Friday, 21 December 2018.

Meanwhile, the S&P BSE Sensex was down 265.86 points, or 0.74% to 35,476.21

On the BSE, 19,000 shares were traded in the counter so far compared with average daily volumes of 13,000 shares in the past two weeks. The stock had hit a high of Rs 200.95 and a low of Rs 193.25 so far during the day.

Unichem Laboratories received final ANDA approval for its Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, and 1.5 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Boehringer Ingelheim Pharmaceuticals Inc.'s Mirapex tablets, 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, and 1.5 mg.

Pramipexole Dihydrochloride Tablets are indicated for the treatment of Parkinson's disease and for the treatment of moderate-to-severe primary restless legs syndrome (RLS).

Unichem Laboratories' net profit dropped 66.8% to Rs 15.21 crore on 12.74% rise in total income to Rs 278.50 crore in Q2 September 2018 over Q2 September 2017.

Unichem Laboratories is an international, integrated, speciality pharmaceutical company.

Powered by Capital Market - Live News